Analytical Techniques

Creative Enzymes

Creative Enzymes has decades of experiences in enzyme expression and purification. We provide a series of services including gene cloning, expression, and fermentation optimization and production of enzymes. The crude enzyme product is then purified properly to be stored or used with stable activities over time. On top of enzyme expression, we also provide the purification service for enzymes from natural sources or customized designs.  You can learn more at  https://www.creative-enzymes.com/service/enzyme-expression-and-purification_68.html

Enzyme Expression and Purification—Creative Enzymes

Teach Me in 10

There is an undeniable art to bench science. From simply pouring a polyacrylamide gel to the more gruelling task of single-cell isolation. Scientists spend years mastering these techniques, but art has its limits. For example, a biopharmaceutical company developing therapeutic monoclonal antibodies needs a fast and reliable way to isolate thousands of B- cell clones or hybridomas. Automated, single-cell isolation systems with precision robotics like CellCelector address this critical need, by providing one-day workflows, with significant benefits compared to fluidics-based alternatives. 

In this episode we speak with Andris Abramenkovs, product manager of CellCelector technology at Sartorius, about how CellCelector transforms single-cell screening and cloning workflows, the unique nanowell arrays, and some of the applications with this technology.

Single-Cell Isolation: When Art is Not Enough

Oncotarget

Oncotarget published this review in Volume 13, entitled, Myeloid-derived suppressor cells: Cancer, autoimmune diseases, and more" by researchers from Department of Comprehensive Cancer Treatment and Research at Aizu, Fukushima Medical University, Fukushima, Japan; Department of Surgery, Cancer Treatment Center, Aizu Chuo Hospital, Fukushima, Japan; Department of Gastrointestinal Tract Surgery, Fukushima Medical University, Fukushima, Japan; Aizu Oncology Consortium, Fukushima, Japan; Department of Surgery, Nippon Medical School, Tokyo, Japan; Department of Surgery, Bange Kousei General Hospital, Fukushima, Japan; Department of Obstetrics and Gynecology, Fukushima Medical University, Fukushima, Japan; Department of Breast Surgery, Fukushima Medical University, Fukushima, Japan; Department of Chest Surgery, Fukushima Medical University, Fukushima, Japan; Department of Radiation Oncology, Fukushima Medical University, Fukushima, Japan; Department of Colorectoanal Surgery, Aizu Medical Center, Fukushima Medical University, Fukushima, Japan; Fukushima Medical University, Fukushima, Japan.

DOI - https://doi.org/10.18632/oncotarget.28303

Correspondence to - Masahiko Shibata - mshibata@fmu.ac.jp

Abstract

Although cancer immunotherapy using immune checkpoint inhibitors (ICIs) has been recognized as one of the major treatment modalities for malignant diseases, the clinical outcome is not uniform in all cancer patients. Myeloid-derived suppressor cells (MDSCs) represent a heterogeneous population of immature myeloid cells that possess various strong immunosuppressive activities involving multiple immunocompetent cells that are significantly accumulated in patients who did not respond well to cancer immunotherapies. We reviewed the perspective of MDSCs with emerging evidence in this review.

Many studies on MDSCs were performed in malignant diseases. Substantial studies on the participation of MDSCs on non-malignant diseases such as chronic infection and autoimmune diseases, and physiological roles in obesity, aging, pregnancy and neonates have yet to be reported. With the growing understanding of the roles of MDSCs, variable therapeutic strategies and agents targeting MDSCs are being investigated, some of which have been used in clinical trials. More studies are required in order to develop more effective strategies against MDSCs.

Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28303

Keywords - MDSC, immunosuppression, Treg, TAM, cancer

About Oncotarget

Oncotarget is a primarily oncology-focused, peer-reviewed, open access journal. Papers are published continuously within yearly volumes in their final and complete form, and then quickly released to Pubmed. On September 15, 2022, Oncotarget was accepted again for indexing by MEDLINE. Oncotarget is now indexed by Medline/PubMed and PMC/PubMed.

To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us:

SoundCloud - https://soundcloud.com/oncotarget
Facebook - https://www.facebook.com/Oncotarget/
Twitter - https://twitter.com/oncotarget
Instagram - https://www.instagram.com/oncotargetjrnl/
YouTube - https://www.youtube.com/OncotargetYouTube
LinkedIn - https://www.linkedin.com/company/oncotarget
Pinterest - https://www.pinterest.com/oncotarget/
Reddit - https://www.reddit.com/user/Oncotarget/

Media Contact
MEDIA@IMPACTJOURNALS.COM
18009220957

Myeloid-Derived Suppressor Cells: Cancer, Autoimmune Diseases, and More

Alfa Chemistry

Alfa Chemistry, a global Contract Research Organization (CRO) specializing in organic chemistry, material chemistry, and medicinal chemistry, is ISO 9001:2015 certified. Alfa Chemistry provides building blocks, research chemicals, reagents, catalysts, and reference materials. We offer more than 80,000 products, custom synthesis, and analytical services. Our products can be searched through the search bar on our website. Please get in touch with us if you would like to receive a copy of our product catalog.

Alfa Chemistry ISO 9001 Certification

Oncotarget published this trending research perspective in Volume 13, entitled, "Treasures from trash in cancer research" by researchers from Núcleo de Pesquisas em Oncologia/Universidade Federal do Pará, Belém, Pará, Brazil; Instituto Metrópole Digital/Universidade Federal do Rio Grande do Norte, Natal, Brazil; Instituto de Ciências Biológicas/Universidade Federal do Pará, Belém, Pará, Brazil.

DOI - https://doi.org/10.18632/oncotarget.28308

Correspondence to - Paulo Pimentel de Assumpção - assumpcaopp@gmail.com

Abstract

Introduction: Cancer research has significantly improved in recent years, primarily due to next-generation sequencing (NGS) technology. Consequently, an enormous amount of genomic and transcriptomic data has been generated. In most cases, the data needed for research goals are used, and unwanted reads are discarded. However, these eliminated data contain relevant information. Aiming to test this hypothesis, genomic and transcriptomic data were acquired from public datasets.

Materials and Methods: Metagenomic tools were used to explore genomic cancer data; additional annotations were used to explore differentially expressed ncRNAs from miRNA experiments, and variants in adjacent to tumor samples from RNA-seq experiments were also investigated.

Results: In all analyses, new data were obtained: from DNA-seq data, microbiome taxonomies were characterized with a similar performance of dedicated metagenomic research; from miRNA-seq data, additional differentially expressed sncRNAs were found; and in tumor and adjacent to tumor tissue data, somatic variants were found.

Conclusions: These findings indicate that unexplored data from NGS experiments could help elucidate carcinogenesis and discover putative biomarkers with clinical applications. Further investigations should be considered for experimental design, providing opportunities to optimize data, saving time and resources while granting access to multiple genomic perspectives from the same sample and experimental run.

Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28308

Keywords - cancer metagenomics, cancer sncRNA expression, RNA-Seq variant calling

About Oncotarget

Oncotarget is a primarily oncology-focused, peer-reviewed, open access journal. Papers are published continuously within yearly volumes in their final and complete form, and then quickly released to Pubmed. On September 15, 2022, Oncotarget was accepted again for indexing by MEDLINE. Oncotarget is now indexed by Medline/PubMed and PMC/PubMed.

To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us:

SoundCloud - https://soundcloud.com/oncotarget
Facebook - https://www.facebook.com/Oncotarget/
Twitter - https://twitter.com/oncotarget
Instagram - https://www.instagram.com/oncotargetjrnl/
YouTube - https://www.youtube.com/OncotargetYouTube
LinkedIn - https://www.linkedin.com/company/oncotarget
Pinterest - https://www.pinterest.com/oncotarget/
Reddit - https://www.reddit.com/user/Oncotarget/

Media Contact
MEDIA@IMPACTJOURNALS.COM
18009220957

Treasures From Trash in Cancer Research

Oncotarget published this research paper in Volume 13, entitled, "Association of fall rate and functional status by APOE genotype in cancer survivors after exercise intervention" by researchers from Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX; Department of Behavioral Neuroscience, Oregon Health and Science University, Portland, OR; School of Nursing, Oregon Health and Science University, Portland, OR; Department of Radiation Medicine, Oregon Health and Science University, Portland, OR; Department of Radiation Oncology, Dartmouth-Hitchcock’s Dartmouth Cancer Center, Lebanon, NH; Knight Cancer Institute, Oregon Health and Science University, Portland, OR; Department of Neurology and Division of Neuroscience, ONPRC, Oregon Health and Science University, Portland, OR.

DOI - https://doi.org/10.18632/oncotarget.28310

Correspondence to - Jacob Raber - raberj@ohsu.edu

Abstract

Purpose/Objectives: Cancer treatment survivors often report impaired functioning and increased falls. Not all survivors experience the same symptom burden, suggesting individual susceptibilities. APOE genotype is a potential genetic risk factor for cancer treatment related side effects. Lifestyle factors such as physical activity can mitigate the effect of APOE genotype on measures of clinical interest in individuals without a history of cancer. We tested the hypothesis that APOE genotype influences cancer treatment related side effects and symptoms as well as response to exercise intervention.

Materials and Methods: Data from a subsample of a study of fall prevention exercise in post-treatment female cancer survivors aged 50–75 years old (https://clinicaltrials.gov NCT01635413) were used to conduct a secondary data analysis. ApoE genotype was determined by serum sampling. Physical functioning, frequency of falls, and symptom burden were assessed using survey instruments.

Results: Data from 126 female cancer survivors a median of 49 months out from cancer diagnosis were analyzed. ApoE4 carriers trended toward a higher fall rate at baseline (p = 0.059), but after exercise intervention had a fall rate lower than E4 non-carriers both immediately after structured intervention (p = 0.013) and after 6 months of follow up (p = 0.002). E2 carriers did not show improved measures of depressive symptoms and self-report disability after exercise intervention. E3 homozygotes showed increased self report physical activity after the 6 month exercise intervention, but E4 and E2 carriers did not.

Conclusions: APOE genotype may modulate cancer treatment related side effects and symptoms and response to exercise intervention.

Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28310

Keywords - apoE, breast cancer, exercise intervention, fall rate, functional status

About Oncotarget

Oncotarget is a primarily oncology-focused, peer-reviewed, open access journal. Papers are published continuously within yearly volumes in their final and complete form, and then quickly released to Pubmed. On September 15, 2022, Oncotarget was accepted again for indexing by MEDLINE. Oncotarget is now indexed by Medline/PubMed and PMC/PubMed.

To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us:

SoundCloud - https://soundcloud.com/oncotarget
Facebook - https://www.facebook.com/Oncotarget/
Twitter - https://twitter.com/oncotarget
Instagram - https://www.instagram.com/oncotargetjrnl/
YouTube - https://www.youtube.com/OncotargetYouTube
LinkedIn - https://www.linkedin.com/company/oncotarget
Pinterest - https://www.pinterest.com/oncotarget/
Reddit - https://www.reddit.com/user/Oncotarget/

Media Contact
MEDIA@IMPACTJOURNALS.COM
18009220957

APOE Genotype Determines Cancer Patients Most Likely to Benefit From Exercise

Scientific Imagers

Camera

Featuring a 24 megapixel coloured digital camera with a superfast autofocus lens inside a dust resistant enclosure, which can be controlled from a PC or a touchscreen. Live view images and capture times of less than a few seconds provides efficient imaging. Gel image acquisition and control software has full function control panel which allows user to adjust camera and lens settings like exposure time settings, focus and aperture (iris). Histogram display on the screen shows image saturation.

Low Noise CMOS imaging sensor
8-bit and 14-bit options
24 megapixel camera
Sharp Zoom lens
Motorized auto-focus
Motorized aperture setting
Manual zoom range 3x
Exposure from 0.00025s onwards
Single/Dual 312nm/365nm/254nm UV
RGB LEDs and convertor screens
Operate camera via PC
Timer for auto-off of UV
Advanced Gel Analysis Software
 

Darkroom Cabinet

The epoxy coated, chemical & corrosion resistant light-tight cabinet has filter holder (1, 3 or 7 filter holder), a UV safety switch and a roll-out transilluminator. The safety switch switches off UV lights as soon as the door is opened. Options for front viewing window with two side windows on the cabinet for excision of bands are also available.

 

Illumination

Standard lighting systems are UV transillumination in 302-312nm* and Epi-white light
Gel filter illumination area is 20x20cm, with 21x26cm option for larger gels. For extra large gels, we also offer a 26x26cm filter.
Gels up to a maximum of 26x26cm can be observed, captured and analysed
Sample size area is 38x30cm
We also offer UV transillumination in dual wavelength (312+365nm being most common)
For rare applications UV transillumination in triple wavelength (254+312+365nm) can also be given
Multi broad band wavelengths can also be offered 254nm, 312nm and 365nm UV trans lights
Intensity control for low and high trans-illumination - low for preparative work and high for quantitative
White light tables are optional to use gel doc for protein gels documentation
For special stains, blue light tables can also be given
Multi-wavelength epi-illumination LEDs are also available for Red, Green, Blue lights for special stains
* Please note that 300nm, 302nm, 306nm and 312nm are in the same range of wavelengths called UV-B (also known as mid-range). Some manufacturers quote 302nm but it is the same as 312nm..

 

Transillumination

Ultraviolet transillumination can be provided in 302-312nm, 365nm or 254nm individual ranges or as Dual or Triple options. Filter size of transilluminator is 20x20 cm, optionally 21x26cm can be provided too. Low & high intensity of 70% & 100% on the transilluminator provides an easy switch between preparative & final imaging. A timer is attached to the transilluminator, which auto switches off UV light in case the user forgets to turn it off. This increases the life of the UV lamps. Trans White & Trans Blue light tables are also available.

 

Epillumination

Epi-white light illumination through dual LED tubes from above is standard. Ultraviolet epi-illumination in a variety of wavelengths can also be provided. For specific stains, epi-light in blue, green or red LEDs can be provided. A combination of all these illumination modes in the same system can be provided.

 

Filter Holder

Standard is manual single position filter holder
Advanced models with 3, 4 and 7-position manual and motorized filter holder are also available
Orange 590 EtBr and clear are standard

Filters

Orange 590: Ethidium Bromide (EtBr), SYPRO Ruby, ProQ Diamond, Deep Purple, etc
Green 520: SYBR Green I, Green II, SYBR Gold, GFP, Fluorescein, FITC
Orange 560: SYBR Safe, Rhodamine, Cy3, etc
Red 630: SYPRO Red, Texas Red, etc
Blue 480: Hoechst, Coumarin, etc
Clear: Coomassie Blue, Silver etc
 

How the Gel Documentation & Imaging Analysis System works

A transilluminator is mounted on roll-out rails inside a light-tight cabinet. To place the gel, the door is opened and transilluminator pulled out. Push it in, close the door and switch on the UV light and camera. The camera is mounted on top of the cabinet along with zoom lens and wavelenght filter (nominally 590nm filter suitable for Ethidium Bromide EtBr gels is provided).

Connect the camera to the PC using the USB cable and gel capture software, to get a real-time live view image of the gel. Adjust camera settings (like shutter speed, aperture, focus) till the optimum image is obtained. Click your images and save them on the PC. A white light epi-illuminations source is also provided, that illuminates objects from top.

With the optional 1D gel analysis software, you can analyse the gels.

 

Package Includes

Dark room cabinet with safety switch
Roll out variable intensity 312nm transilluminator
Epi-white light illumination
24 megapixel camera
Gel capture software
590nm filter, suitable for EtBr stained gels
Power cords, USB cable, instruction manual, warranty card

Gel Documentation Systems

XenoTech

Presenter: Brian Ogilvie, Ph.D, Vice President of Scientific Consulting at XenoTech

In June 2022, the ICH released the first draft of its harmonized Drug Interaction Studies Guideline (M12). The guideline is the result of several meetings of the Expert Working Group since 2018 with the goal of harmonizing member regulatory agencies’ guidelines to create a single guideline that will be used across all member countries. After a review period, the guideline will be adopted in early 2024.

Hear expert Dr. Brian Ogilvie discuss the differences between current in vitro drug-drug interaction guidance from the relevant US FDA, EMA and PMDA guidance documents, and how to plan drug development strategies to meet the ICH M12 guideline.

Request a copy of the slides: https://www.xenotech.com/about/events/webinar-highlights-of-the-in-vitro-sections-of-the-draft-ich-drug-interaction-studies-guideline-and-comparison-with-current-guidance/
Questions, comments and requests: https://www.xenotech.com/contact-us 
More information on our research services and test systems: https://www.xenotech.com
Other previously aired webinars: https://www.xenotech.com/scientific-resources/webinar-series
Upcoming webinar notifications: https://www.xenotech.com/newsletter-signup
Request a webinar topic: https://www.xenotech.com/scientific-resources/upcoming-webinars

About the Presenter:
As Vice President of Scientific Consulting at XenoTech, Dr. Brian Ogilvie is responsible for operational activities within the Scientific Consulting and Quality Assurance departments, as well as strategic planning for the company in scientifically relevant areas. Dr. Ogilvie obtained his Ph.D. in toxicology from the University of Kansas Medical Center and B.A. in molecular biology from William Jewell College. Brian joined XenoTech in 1997 as a Scientist I and progressed into leadership as the head of the CYP Inhibition Department in 1999, with increasing levels of responsibility, ultimately to the current Vice President role. Dr. Ogilvie also serves as a Volunteer Assistant Professor of Pharmacology, Toxicology and Therapeutics for the University of Kansas Medical Center. He is an author or coauthor on over 50 scientific posters, peer-reviewed publications and book chapters on the topics of drug metabolism, transport and drug-drug interactions, and has represented XenoTech as an invited speaker at various drug metabolism conferences.

Highlights of the In Vitro Sections of the Draft ICH Drug Interaction Studies Guideline and Comparison with Current Guidance

Oncotarget published this trending research paper in Volume 13, entitled, "Mutation analysis performed on tumor biopsies from patients with newly-diagnosed germinal center aggressive B cell lymphomas" by researchers from the Department of Medicine University of Pennsylvania, Philadelphia, PA.
#openaccess #research #germinalcancer #lymphoma #cancer #oncologyresearch #peerreview #openscience #chemotherapy

DOI - https://doi.org/10.18632/oncotarget.28309

Correspondence to - Daniel J. Landsburg - daniel.landsburg@pennmedicine.upenn.edu 

Abstract

Comprehensive genomic analyses of tumor biopsies from patients with newly-diagnosed germinal center B cell (GCB) diffuse large B cell/high grade B cell lymphoma (DLBCL/HGBL) have identified molecular subtypes predictive of inferior survival, which are characterized by somatic mutations that can be detected through clinical laboratory mutation analysis (CLMA). To determine the frequency and predictive value of individual genetic mutations associated with these experimentally-defined poor-risk subgroups, we reviewed the findings from CLMA performed on tumors from patients with newly-diagnosed GCB DLBCL/HGBL who were previously treated at our institution. CLMA was successfully performed on 58/59 patient tumor biopsies with a median turnaround time of 16 days, and 51 on which CLMA was routinely performed with adequate clinical follow-up were analyzed. Patients whose tumors demonstrated CREBBP mutation experienced a lower estimated rate of 2-year disease free survival (DFS) as compared to those whose tumors did not (45% [95% CI 18–68%] vs. 67% [95% CI 44–83%], P = 0.045). CREBBP mutations may be frequent and predict for inferior DFS in patients with newly-diagnosed GCB DLBCL/HGBL. Furthermore, CLMA may be practically-applied to translate experimental findings into those with more direct application to risk stratification and clinical trial design in subsets of patients with DLBCL/HGBL.

Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28309

Press release - https://www.oncotarget.com/news/pr/oncotarget-mutation-analysis-performed-on-tumor-biopsies-from-patients-with-newly-diagnosed-germinal-center-aggressive-b-cell-lymphomas/

Keywords - diffuse large B cell lymphoma, high grade B cell lymphoma, mutation analysis, next generation sequencing, chemotherapy

About Oncotarget

Oncotarget is a primarily oncology-focused, peer-reviewed, open access journal. Papers are published continuously within yearly volumes in their final and complete form, and then quickly released to Pubmed. On September 15, 2022, Oncotarget was accepted again for indexing by MEDLINE. Oncotarget is now indexed by Medline/PubMed and PMC/PubMed.

To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us:

SoundCloud - https://soundcloud.com/oncotarget
Facebook - https://www.facebook.com/Oncotarget/
Twitter - https://twitter.com/oncotarget
Instagram - https://www.instagram.com/oncotargetjrnl/
YouTube - https://www.youtube.com/OncotargetYouTube
LinkedIn - https://www.linkedin.com/company/oncotarget
Pinterest - https://www.pinterest.com/oncotarget/
Reddit - https://www.reddit.com/user/Oncotarget/

Media Contact
MEDIA@IMPACTJOURNALS.COM
18009220957

Analytical Techniques

Refine By

Keep up to date with all your favourite videos and channels.

Get personalised notifications on new releases and channel content by subscribing to the LabTube eNewsletter.